Home
APRE
APRE News

Latest Aprea Therapeutics Inc. Common stock (APRE) News on November 4, 2025

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

GlobeNewswire

11 days ago

Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

GlobeNewswire

20 days ago

Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination Therapies

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire

21 days ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

GlobeNewswire

3 months ago

Aprea Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Clinical Update

MT Newswires

4 months ago

Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer

Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock

Simply Wall St.

4 months ago

Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

GlobeNewswire

4 months ago

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation WEE1 Inhibitor, APR-1051, in HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Collaboration with MD Anderson Cancer Center

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

GlobeNewswire

6 months ago

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial

Clinical Trials Arena

7 months ago

Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

GlobeNewswire

7 months ago

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire

7 months ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

GlobeNewswire

8 months ago

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Aprea Therapeutics provides update on existing patent portfolio

TipRanks

9 months ago

Aprea Therapeutics provides update on existing patent portfolio

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

GlobeNewswire

9 months ago

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

GlobeNewswire

a year ago

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher

Zacks

a year ago

Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher

Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates

Zacks

a year ago

Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Pacira (PCRX) Q3 Earnings Beat Estimates

Zacks

a year ago

Pacira (PCRX) Q3 Earnings Beat Estimates

Aprea Therapeutics presents preliminary results on APR-1051

TipRanks

a year ago

Aprea Therapeutics presents preliminary results on APR-1051

Insider Spends US$132k Buying More Shares In Aprea Therapeutics

Simply Wall St.

a year ago

Insider Spends US$132k Buying More Shares In Aprea Therapeutics

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

GlobeNewswire

a year ago

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/18/2024

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/17/2024

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 10/16/2024

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

GlobeNewswire

a year ago

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc

GuruFocus.com

a year ago

Stonepine Capital Management, LLC Increases Stake in Aprea Therapeutics Inc

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

GlobeNewswire

a year ago

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

GlobeNewswire

a year ago

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

GlobeNewswire

a year ago

Aprea Therapeutics to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

GlobeNewswire

a year ago

Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

GlobeNewswire

a year ago

Life Sciences Virtual Investor Forum Agenda Announced for September 19th

Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19

GlobeNewswire

a year ago

Aprea Therapeutics to Present at the Life Sciences Investor Forum on September 19

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

GlobeNewswire

a year ago

UPDATE - Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

GlobeNewswire

a year ago

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

GlobeNewswire

a year ago

Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference

Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates

Zacks

a year ago

Aprea Therapeutics, Inc. (APRE) Reports Q2 Loss, Tops Revenue Estimates

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire

a year ago

Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?

Simply Wall St.

a year ago

Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

GlobeNewswire

a year ago

Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

GlobeNewswire

a year ago

Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051

Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock

Simply Wall St.

a year ago

Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

GlobeNewswire

a year ago

Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire

a year ago

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

GlobeNewswire

a year ago

Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 years ago

Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

GlobeNewswire

2 years ago

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

GlobeNewswire

2 years ago

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

GlobeNewswire

2 years ago

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

GlobeNewswire

2 years ago

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

GlobeNewswire

2 years ago

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

GlobeNewswire

2 years ago

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

GlobeNewswire

2 years ago

Synlogic Announces Publication of Preclinical and Clinical Data for SYNB1353 as a Potential Treatment for Classical Homocystinuria

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

GlobeNewswire

2 years ago

Aprea Therapeutics to Present at DDR Inhibitors Summit 2024

Aware Adds Product Strategy Innovator to Executive Team to Further Align Biometric Platform and Vision with Market Growth

GlobeNewswire

2 years ago

Aware Adds Product Strategy Innovator to Executive Team to Further Align Biometric Platform and Vision with Market Growth

Bitcoin Depot Places Order for 500 New BTM Kiosks from Kiosk Provider Genmega

GlobeNewswire

2 years ago

Bitcoin Depot Places Order for 500 New BTM Kiosks from Kiosk Provider Genmega

Adlucent achieves Google Cloud Partner status, strengthening client solutions

GlobeNewswire

2 years ago

Adlucent achieves Google Cloud Partner status, strengthening client solutions

VCI Global Announces Pricing of $2.75 Million Public Offering

GlobeNewswire

2 years ago

VCI Global Announces Pricing of $2.75 Million Public Offering

Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?

Simply Wall St.

2 years ago

Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease

GlobeNewswire

2 years ago

OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease

17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

GlobeNewswire

2 years ago

17EdTech Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

GlobeNewswire

2 years ago

Aprea Therapeutics Provides Corporate Update and Announces Development Plans for 2024

Bullish Aspira Women's Health Insiders Loaded Up On US$702.9k Of Stock

Simply Wall St.

2 years ago

Bullish Aspira Women's Health Insiders Loaded Up On US$702.9k Of Stock

Canadian Investment Regulatory Organization Trading Halt - DGHI

CNW Group

2 years ago

Canadian Investment Regulatory Organization Trading Halt - DGHI

3 Tech Stocks Under $10 to Boost Your Portfolio in 2024

Zacks

2 years ago

3 Tech Stocks Under $10 to Boost Your Portfolio in 2024

Know Labs Expands Medical and Scientific Advisory Board

Business Wire

2 years ago

Know Labs Expands Medical and Scientific Advisory Board

Perma-Pipe International Holdings (NASDAQ:PPIH) Is Experiencing Growth In Returns On Capital

Simply Wall St.

2 years ago

Perma-Pipe International Holdings (NASDAQ:PPIH) Is Experiencing Growth In Returns On Capital

180 Degree Capital Corp. Notes Appointment of Kevin M. Rendino to the Board of Directors of Its Portfolio Company, Synchronoss Technologies, Inc.

GlobeNewswire

2 years ago

180 Degree Capital Corp. Notes Appointment of Kevin M. Rendino to the Board of Directors of Its Portfolio Company, Synchronoss Technologies, Inc.

Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now

GlobeNewswire

2 years ago

Presenting on the Emerging Growth Conference 65 Day 1 on December 6th Register Now

The Joint Corp. to Participate in the 12th Annual Roth Deer Valley Conference

GlobeNewswire

2 years ago

The Joint Corp. to Participate in the 12th Annual Roth Deer Valley Conference

Is It Too Late To Consider Buying DarioHealth Corp. (NASDAQ:DRIO)?

Simply Wall St.

2 years ago

Is It Too Late To Consider Buying DarioHealth Corp. (NASDAQ:DRIO)?

Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of November 30, 2023, for TYG, NTG, TTP, NDP and TPZ

ACCESSWIRE

2 years ago

Tortoise Provides Unaudited Balance Sheet Information and Asset Coverage Ratio Updates as of November 30, 2023, for TYG, NTG, TTP, NDP and TPZ

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

GlobeNewswire

2 years ago

MediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial Officer

Plutonian Acquisition Corp. Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination

PR Newswire

2 years ago

Plutonian Acquisition Corp. Announces Additional Contribution to Trust Account to Extend Period to Consummate Business Combination

Associated Press Finance

2 years ago

Cross Timbers: Q3 Earnings Snapshot

Li-Cycle Reports Third Quarter 2023 Financial Results and Provides Business Update

Business Wire

2 years ago

Li-Cycle Reports Third Quarter 2023 Financial Results and Provides Business Update

Toro Third Quarter 2023 Earnings: EPS: US$1.79 (vs US$1.92 in 3Q 2022)

Simply Wall St.

2 years ago

Toro Third Quarter 2023 Earnings: EPS: US$1.79 (vs US$1.92 in 3Q 2022)

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

GlobeNewswire

2 years ago

Aprea Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update

MEDIROM Healthcare Technologies (NASDAQ:MRM) Might Be Having Difficulty Using Its Capital Effectively

Simply Wall St.

2 years ago

MEDIROM Healthcare Technologies (NASDAQ:MRM) Might Be Having Difficulty Using Its Capital Effectively

Landmark Bancorp (NASDAQ:LARK) Will Pay A Dividend Of $0.21

Simply Wall St.

2 years ago

Landmark Bancorp (NASDAQ:LARK) Will Pay A Dividend Of $0.21

Share on Social Networks: